On Nov 01, major Wall Street analysts update their ratings for $Zimmer Biomet Holdings (ZBH.US)$, with price targets ranging from $117 to $140.
Morgan Stanley analyst Drew Ranieri maintains with a hold rating, and adjusts the target price from $118 to $122.
Oppenheimer analyst Steven Lichtman maintains with a buy rating, and maintains the target price at $135.
Needham analyst Michael Matson maintains with a hold rating.
Stifel analyst Rick Wise maintains with a buy rating, and maintains the target price at $130.
Truist Financial analyst Richard Newitter maintains with a hold rating, and sets the target price at $117.
Furthermore, according to the comprehensive report, the opinions of $Zimmer Biomet Holdings (ZBH.US)$'s main analysts recently are as follows:
Zimmer Biomet reported Q3 sales that surpassed consensus forecasts, with EPS meeting expectations. The anticipated impact on ERP has been revised to a range of 60-80 basis points for the second half of the year, compared to the 100 basis points estimated earlier. Additionally, forecasts for 2024 sales growth and EPS have been adjusted to 4.25-4.75% and $7.95-8.05, respectively.
Here are the latest investment ratings and price targets for $Zimmer Biomet Holdings (ZBH.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
